A range of new and existing backers have added $45m to ViaCyte’s series D round, which now stands at more than $115m.

ViaCyte, a US-based diabetes treatment developer backed by corporates WL Gore, Johnson & Johnson and Hospira, has secured $45m to bring its series D round to more than $115m.

Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures and Artis Ventures supplied the latest funding.

The company had disclosed $27m of series D funding from Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures and unnamed private investors

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn